Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection

Brigham and Women's Hospital1 site in 1 country8 target enrollmentMay 30, 2018

Overview

Brief Summary

The purpose of this study is to determine the feasibility and efficacy of detecting kidney transplant rejection using contrast enhance ultrasonography with the contrast agent Sonazoid.

Detailed Description

This study will be divided into two stages. In the first stage the investigators will assess the transplant kidney with ultrasound after contrast injection (Sonazoid) to determine if contrast in the kidney is detectable by ultrasound and to determine if the amount of perfusion can be quantified directly or qualitatively. The investigators aim to have one to two subjects in this stage. If perfusion of the kidney can be assessed, then the investigators will move to stage two of the study. In stage 2, the investigators will look to determine the ability of the contrast enhanced ultrasonography method to detect renal transplant rejection using Sonazoid. For this stage the investigators will recruit subjects with biopsy confirmed renal transplant rejection. Once subjects are consented, they will undergo contrast enhanced ultrasonography with Sonazoid and have images taken. These images will be compared to images of renal transplant patients that have displayed no rejection or clinical issues. These clinically normal subjects will have previously consented to a medical record review so that the investigators may use their images.

Registry

clinicaltrials.gov

Start Date

May 30, 2018

End Date

February 1, 2023

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Brigham and Women's Hospital

Responsible Party

Principal Investigator

Andrew Michael Siedlecki

Transplant Nephrologist

Brigham and Women's Hospital

Eligibility Criteria

Inclusion Criteria

•Adults (ages 18-75) who have undergone renal transplant at the Brigham and Women's Hospital. \[For stage 1 or stage 2\]
•Experiencing acute and chronic renal allograft rejection - defined by by examining the histological sections of renal transplant biopsy for a renal pathologist. This is the most accurate way to evaluate the presence of absence of acute and chronic renal transplant biopsy. \[For stage 2\]
•Adults (ages 18-75) who have undergone renal transplant at the Brigham and Women's Hospital with normal serum creatinine values (\~1 mg/dl) \[For stage 2 medical record review only\]

Exclusion Criteria

•Hemodynamic instability (e.g., blood pressure \< 90)
•Atrial fibrillation with rapid ventricular response
•Arrhythmia
•Poor acoustic windows
•Inability to provide informed consent
•Known right to left or bidirectional cardiac shunts
•Any contraindication such as the history of allergic reactions
•Pregnant or nursing women

Arms & Interventions

Sonazoid contrast

The contrast agent Sonazoid will be used during contrast enhanced ultrasonography. This will be a one-time administration of the contrast agent. The contrast agent, Sonazoid (GE Healthcare), is a lipid-stabilized suspension of perfluorobutane microbubbles with a median diameter of 2.4-3.5 μm and will be administered per package insert (intravenously as a continuous infusion). Sonazoid contrast agent will be given at a dose 0.0075 mL/Kg as a bolus intravenous injection while visualizing the kidney transplant.

Intervention: Sonazoid

Sonazoid contrast

The contrast agent Sonazoid will be used during contrast enhanced ultrasonography. This will be a one-time administration of the contrast agent. The contrast agent, Sonazoid (GE Healthcare), is a lipid-stabilized suspension of perfluorobutane microbubbles with a median diameter of 2.4-3.5 μm and will be administered per package insert (intravenously as a continuous infusion). Sonazoid contrast agent will be given at a dose 0.0075 mL/Kg as a bolus intravenous injection while visualizing the kidney transplant.

Intervention: contrast enhanced ultrasonography